Zometa, manufactured by Novartis, has been linked to a serious bone disease called Osteonecrosis of the Jaw (ONJ), osteomyelitis, or dead jaw. In addition, the drug has been linked to Zometa-induced femur and hip fractures.
What is the problem with Zometa?
Zometa is in a class called bisphosphonates along with Actonel, Aredia, Boniva, Fosamax, Reclast and Zometa to prevent and treat osteoporosis. These drugs are also used at an earlier age in over 36 million women due to the increased risks that come along with hormone replacement therapy. Because women use these drugs at an earlier age and for longer time spans, they are more prone to developing Osteonecrosis of the Jaw (ONJ). Signs and symptoms of ONJ include pain, loosening of the teeth, swelling or infection of the gums, poor healing of gums, drainage and exposed gums. Since 2001, there have been over 2,400 reported cases of jaw bone decay and death or ONJ after the use of Fosamax (also a bisphosphonates). The pain from this bone disease is so debilitating that there have been over 120 patients who have become bedridden or who now rely on wheelchairs, walkers or crutches.
Side Effects of Zometa
There are a variety of side effects associated with Zometa. Our firm is pursing the following types of severe side effects:
- Osteonecrosis of the Jaw
- Dead Jaw
- Swelling or infection of the gums
- Loosening of the teeth
- Poor healing of the gums
- Numbness or a feeling of heaviness in the jaw
- Exposed bone
- Hip Fractures
- Femur Fractures